View Older Stories View More Recent Stories
-
Mizuho Downgrades Terns Pharmaceuticals (TERN) to Neutral on Merck acquisition
-
Guggenheim Reiterates Buy Rating on Merck (MRK)
-
TD Cowen Downgrades Terns Pharmaceuticals (TERN) to Hold
-
BofA Securities on Merck (MRK): Terns adds to 2025 deals for de-risked drugs 'with growth expected during Keytrude LOE period'
-
Morgan Stanley on Merck (MRK): Terns acquisition 'encouraging and consistent with prior commentary'
-
H.C. Wainwright Downgrades Terns Pharmaceuticals (TERN) to Neutral
-
Barclays on Merck (MRK): Terns deal shows Merck shifting toward 'more diversified onco strategy'
-
Truist Securities stays Buy on Terns Pharmaceuticals (TERN) as Merck acquires 'for a steal'
-
Enliven Therapeutics stock surges 28% on Merck-Terns deal
-
Merck to buy oncology firm Terns Pharmaceuticals in $6.7 billion deal
-
Merck (MRK) Nears $6b Deal To Buy Terns Pharma (TERN) - FT
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
US Judge blocks Trump Admin cuts to number of routinely recommended vaccines for children - Reuters
-
Merck to present data on cholesterol and heart failure drugs at ACC.26
-
Merck (MRK) PT Raised to $150 at Wells Fargo
-
Merck (MRK) PT Raised to $129 at Leerink Partners
-
Merck's KEYTRUDA plus Padcev reduces bladder cancer risk in trial
-
RBC Capital Starts Merck (MRK) at Outperform
-
Merck restructures human health division into two business units
-
Merck splits pharmaceuticals unit into two divisions ahead of patent loss
-
Merck (MRK) to split human-health business into two divisions - WSJ
-
Barclays Starts Merck (MRK) at Overweight
-
Merck reports positive second-season data for RSV drug in high-risk children
-
Merck and Mayo Clinic partner on AI drug discovery collaboration
-
Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent
-
Deutsche Bank Upgrades Merck (MRK) to Buy
-
Merck presents cancer treatment data at ASCO GU symposium
-
FDA approves Merck's KEYTRUDA and KEYTRUDA QLEX for ovarian cancer
-
FDA approves Merck's (MRK) Keytruda for platinum-resistant ovarian cancer patients
-
Merck (MRK): FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, primary peritoneal carcinoma
-
Merck (MRK) PT Raised to $140 at Guggenheim, 'continue to see MRK as one of our Top Picks'
-
Merck (MRK) PT Raised to $100 at Bernstein SocGen Group
-
Merck (MRK) PT Raised to $135 at Wells Fargo
-
Merck (MRK) PT Raised to $109 at Morgan Stanley
-
Merck (MRK) PT Raised to $132 at BofA Securities
-
Merck (MRK) PT Raised to $135 at BMO Capital
-
Merck shares fall as 2026 guidance disappoints despite solid Q4 results
-
Merck (MRK) Reports In-Line Q4 EPS; offers guidance
-
Merck preview: focus on post-Keytruda growth path
-
Merck (MRK) call put ratio 2.1 calls to 1 put into quarter results
-
Merck (MRK) call put ratio 1.7 calls to 1 put into quarter results
-
Merck (MRK) call put ratio 1 call to 1.9 puts into quarter results
-
Merck (MRK) call put ratio 1.7 calls to 1 put into quarter results
-
Merck Is Said To Seek $30M Stake In Eikon Therapeutics IPO - Bloomberg
-
Merck (MRK) Declares $0.85 Quarterly Dividend; 3.2% Yield
-
Truist Securities keeps Revolution (RVMD) at Buy, 'believe that RVMD is well funded and doesn't need to do a deal'
-
Revolution Medicines stock falls after Merck reportedly ends acquisition pursuit
-
Merck ends acquisition talks with Revolution Medicines - WSJ
-
This U.S. biotech stock is Bernstein's Top Pick for 2026
-
Merck (MRK) Added to BofA US 1 List, Apple (AAPL) Remains On
